Related Experiment Video

Updated: Apr 30, 2026

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

1.4K

Galectin-3: a modifiable risk factor in heart failure

Rudolf A de Boer1, A Rogier van der Velde, Christian Mueller

  • 1Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands, r.a.de.boer@umcg.nl.

Cardiovascular Drugs and Therapy
|May 3, 2014
PubMed

Insights

Galectin-3 (a protein) increases with heart failure and may cause fibrosis. Inhibiting galectin-3 shows promise as a novel heart failure therapy, but clinical studies are needed.

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • Myocardial galectin-3 elevates with cardiac stressors like angiotensin II and pressure overload.
  • Galectin-3 expression correlates with heart failure progression and severity, establishing its role as a biomarker.
  • Galectin-3 is causally linked to pathological myocardial fibrosis, suggesting active contribution to heart failure development.

Purpose of the Study:

  • To review the potential of galectin-3 as a therapeutic target for heart failure.
  • To discuss the mechanisms by which galectin-3 contributes to heart failure.
  • To evaluate the efficacy of galectin-3 inhibition as a treatment strategy.

Main Methods:

  • Literature review of experimental and clinical studies on galectin-3 in heart failure.
  • Analysis of the interaction between galectin-3 and other pro-fibrotic factors like aldosterone.
  • Discussion of ongoing therapeutic strategies targeting galectin-3.

Main Results:

  • Galectin-3 upregulation is a key feature of cardiac remodeling and heart failure.
  • Experimental evidence supports galectin-3 inhibition as a potential therapeutic approach.
  • A significant interaction between galectin-3 and aldosterone, a pro-fibrotic factor, has been identified.

Conclusions:

  • Galectin-3 plays a causal role in myocardial fibrosis and heart failure progression.
  • Inhibiting galectin-3 may offer a novel therapeutic avenue for treating heart failure.
  • Further clinical studies are required to validate galectin-3-targeted treatments and establish specific regimens.

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.3K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
1.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K